{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Troxacitabine_Nucleotide_Prodrug_MIV-818",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A liver-targeting nucleotide phosphoramidate prodrug of troxacitabine monophosphate (TRX-MP), a dioxolane derivative and L-configuration deoxycytidine analogue, with potential antineoplastic activity. Upon oral administration, MIV-818 is rapidly and specifically hydrolyzed in hepatocytes by liver carboxylesterase 1 (carboxylesterase 1, CE-1), generating high levels of the chain-terminating nucleotide, troxacitabine triphosphate (TRX-TP) in the liver. TRX-TP is then incorporated into tumor cell DNA, leading to termination of DNA synthesis and inhibition of tumor cell proliferation.",
    "fdaUniiCode": "Q1I6YZ0NGF",
    "identifier": "C157496",
    "preferredName": "Troxacitabine Nucleotide Prodrug MIV-818",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1557"
    ],
    "synonyms": [
      "MIV 818",
      "MIV-818",
      "MIV818",
      "Troxacitabine Nucleotide Prodrug MIV-818",
      "Troxacitabine Prodrug MIV-818"
    ]
  }
}